Aquestive Therapeutics News - August 2026
Aquestive Therapeutics second quarter 2026 revenue of $13.8M missed estimates as Anaphylm resubmission remains on track
Aquestive Therapeutics reported second quarter 2026 revenue of $13.8 million, representing a 38% increase year-over-year but falling short of the $14.2 million...
🟢 Aquestive Therapeutics is trading 13.96% up today after Anaphylm studies cleared a key FDA hurdle
Aquestive Therapeutics is trading 13.96% up now at $4.49 after Anaphylm’s usability and drug-absorption studies cleared a key FDA hurdle, strengthening the...
Aquestive Clears a Key FDA Hurdle for Its Needle-Free Allergy Drug — But Can a $630 Million Company Really Take On EpiPen?
Shares of Aquestive Therapeutics jumped +9.1% to $4.30 Monday morning after the company reported that its under-the-tongue epinephrine film — a...
🟢 Aquestive Therapeutics is trading 9.14% up in pre-market after positive Anaphylm usability and pharmacokinetic results
Aquestive Therapeutics is trading at $4.30 (+9.14%) after announcing positive topline human-factors and pharmacokinetic study results for Anaphylm. - The data...
Aquestive Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Wall Street analysts expect Aquestive Therapeutics to report Q2 2026 revenue of $14.22 million and a net loss of $0.11 per share, with the current $4.25 share...